Profile data is unavailable for this security.
About the company
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
- Revenue in USD (TTM)2.24bn
- Net income in USD798.86m
- Incorporated2020
- Employees89.00
- LocationRoyalty Pharma PLC110 East 59th StreetNEW YORK 10022United StatesUSA
- Phone+1 (212) 883-0200
- Websitehttps://www.royaltypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grayscale Ethereum Trust (ETH) | 0.00 | 5.19bn | 9.66bn | -- | 1.86 | 0.9022 | 1.86 | -- | 16.73 | 16.73 | 0.00 | 34.53 | 0.00 | -- | -- | -- | 63.94 | 26.33 | 63.94 | 26.33 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | 140.36 | -- | -- | -- |
| Annaly Capital Management, Inc. | 4.00bn | -482.89m | 10.12bn | 187.00 | -- | 1.02 | -- | 2.53 | -0.9787 | -0.9787 | 8.04 | 22.80 | 0.0449 | -- | 4.94 | 21,384,570.00 | -0.3746 | -0.1192 | -1.36 | -0.4917 | -3.66 | 8.17 | -8.35 | -5.75 | -- | -- | 0.8694 | -- | -26.28 | 1.06 | -210.54 | -- | -18.06 | -10.03 |
| Ares Capital Corporation | 2.70bn | 1.69bn | 12.71bn | 2.80k | 7.08 | 1.06 | 28.30 | 4.71 | 2.92 | 2.92 | 4.62 | 19.53 | 0.1171 | -- | 8.20 | 963,214.30 | 7.35 | 5.36 | 7.54 | 5.53 | 49.68 | 52.41 | 62.77 | 51.90 | -- | -- | 0.497 | 83.53 | 24.71 | 14.35 | 153.67 | 12.15 | -- | 4.51 |
| Royalty Pharma plc | 2.24bn | 798.86m | 16.08bn | 89.00 | 15.10 | 1.87 | 13.50 | 7.18 | 1.78 | 1.78 | 3.73 | 14.41 | 0.1348 | -- | 73.80 | 25,152,370.00 | 7.15 | 9.57 | 9.60 | 12.42 | -- | -- | 53.01 | 67.80 | -- | -- | 0.3836 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Texas Pacific Land Corp | 659.38m | 433.49m | 17.24bn | 100.00 | 39.86 | 15.36 | 38.42 | 26.15 | 18.82 | 18.82 | 28.62 | 48.82 | 0.5955 | -- | 5.79 | 6,593,750.00 | 39.15 | 45.77 | 41.69 | 48.13 | 94.22 | 96.10 | 65.74 | 63.58 | -- | -- | 0.00 | 42.12 | -5.37 | 16.04 | -9.12 | 14.10 | -5.86 | 63.45 |
| Grayscale Bitcoin Trust (Btc) | 0.00 | 15.89bn | 18.63bn | -- | 2.54 | 1.53 | 1.17 | -- | 22.94 | 22.94 | 0.00 | 38.06 | 0.00 | -- | -- | -- | 86.30 | 25.26 | 86.30 | 25.26 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 183.12 | -- | -- | -- |
| State Street Corp | 9.75bn | 1.71bn | 21.36bn | 45.87k | 13.25 | 0.9734 | 7.82 | 1.78 | 5.35 | 5.35 | 37.83 | 81.04 | -- | -- | -- | -- | 0.591 | 0.8342 | -- | -- | -- | -- | 15.51 | 20.27 | -- | -- | -- | 34.89 | 117.47 | 19.34 | -31.54 | -5.15 | 6.03 | 8.32 |
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 37.96m | 8.50% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 36.74m | 8.23% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 31.19m | 6.98% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 16.66m | 3.73% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 15.37m | 3.44% |
| Viking Global Investors LPas of 31 Mar 2024 | 11.49m | 2.57% |
| Adage Capital Management LPas of 31 Mar 2024 | 10.82m | 2.42% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.10m | 2.04% |
| Swedbank Robur Fonder ABas of 31 Mar 2024 | 8.28m | 1.85% |
| Geode Capital Management LLCas of 31 Mar 2024 | 6.55m | 1.47% |
